Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | ELANE | P08246 | 9/20 | 0.38 |
| ▸ | KIF11 | P52732 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 3/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10395593 | 0.88 | MAPT (0.40) | MAPTTDP1L3MBTL1ELANEKIF11 | |
| SCHEMBL9575659 | 0.82 | KIF11 (0.54) | KIF11 | |
| SCHEMBL10395579 | 0.81 | ESR1 (0.44) | MAPTTDP1L3MBTL1ELANEKIF11 | |
| SCHEMBL9575156 | 0.81 | KIF11 (0.41) | MAPTTDP1L3MBTL1ELANEKIF11 | |
| SCHEMBL9575396 | 0.78 | LMNA (0.55) | MAPTL3MBTL1ELANEKMT2AATM | |
| SCHEMBL15834836 | 0.77 | KIF11 (0.43) | MAPTTDP1ELANEKIF11RAB9A | |
| SCHEMBL9575401 | 0.76 | KMT2A (0.41) | ELANESMN1; SMN2KMT2AMEN1ATM | |
| SCHEMBL11422436 | 0.76 | LMNA (0.57) | MAPTTDP1L3MBTL1ELANESMN1; SMN2 | |
| SCHEMBL15836489 | 0.76 | HSD11B1 (0.49) | ELANEKIF11KMT2AHSD11B1ATM | |
| SCHEMBL23963176 | 0.75 | THRB (0.53) | MAPTTDP1L3MBTL1ELANERAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10919870-B2 | Polymerizable compound and optically anisotropic body | DIC CORPORATION (JP) | 2021-02-16 | — | — | US | disclosed |
| WO-2017079867-A1 | POLYMERIZABLE COMPOUND AND OPTICALLY ANISOTROPIC BODY | DIC CORPORATION (JP) | 2017-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10919870-B2 | Polymerizable compound and optically anisotropic body | ZYX, ZW10, DPY30 | MAPT 545/4885TDP1 830/4885L3MBTL1 801/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.